{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:47:34Z","timestamp":1762642054673},"reference-count":112,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ackdjournal.org","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1053\/j.ackd.2017.11.002","type":"journal-article","created":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T14:11:01Z","timestamp":1521814261000},"page":"158-165","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition"],"prefix":"10.1053","volume":"25","author":[{"given":"Vikram","family":"Patney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunal","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Whaley-Connell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2017.11.002_bib1","series-title":"IDF diabetes Atlas\u20137th edition","year":"2015"},{"key":"10.1053\/j.ackd.2017.11.002_bib2","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000452283","article-title":"The central role of endothelial dysfunction in cardiorenal syndrome","volume":"7","author":"Zhang","year":"2017","journal-title":"Cardiorenal Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1053\/j.ajkd.2014.08.001","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"64","author":"Tuttle","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2017.11.002_bib4","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1046\/j.1523-1755.2001.00020.x","article-title":"Diabetic nephropathy: prevention and treatment","volume":"60","author":"Parving","year":"2001","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2017.11.002_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2337\/dc09-0343","article-title":"Incidence of treatment for end stage renal disease among individuals with diabetes in the U.S. continues to decline","volume":"33","author":"Burrows","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2017.11.002_bib6","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","article-title":"Changes in diabetes-related complications in the United States, 1990-2010","volume":"370","author":"Gregg","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38","volume":"317","year":"1998","journal-title":"Br Med J"},{"key":"10.1053\/j.ackd.2017.11.002_bib8","series-title":"2010 Annual data report: Atlas of chronic kidney disease and end stage renal disease in United States","year":"2010"},{"key":"10.1053\/j.ackd.2017.11.002_bib9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib10","series-title":"2013 Annual data report: Atlas of chronic kidney disease and end stage renal disease in the United States","year":"2013"},{"issue":"Suppl. 1","key":"10.1053\/j.ackd.2017.11.002_bib11","doi-asserted-by":"crossref","first-page":"A7","DOI":"10.1053\/j.ajkd.2013.11.001","article-title":"U.S. Renal data system 2013 annual data report","volume":"63","author":"Collins","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2017.11.002_bib12","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000455905","article-title":"Prognostic implications of chronic kidney disease on patients presenting with ST-segment elevation myocardial infarction with versus without stent thrombosis","volume":"7","author":"Margolis","year":"2017","journal-title":"Cardiorenal Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib13","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1053\/ajkd.2000.16225","article-title":"Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group","volume":"36","author":"Bakris","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2017.11.002_bib14","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF00404089","article-title":"Prevalence of hypertension in type 1 (insulin dependent) diabetes mellitus","volume":"33","author":"Norgaard","year":"1990","journal-title":"Diabetologia"},{"key":"10.1053\/j.ackd.2017.11.002_bib15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2337\/diaspect.28.3.175","article-title":"Hypertension management in diabetic kidney disease","volume":"28","author":"Vikram","year":"2015","journal-title":"Diabetes Spectr"},{"key":"10.1053\/j.ackd.2017.11.002_bib16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ackd.2010.10.003","article-title":"Hypertension in diabetic nephropathy: epidemiology, mechanisms and management","volume":"18","author":"Van Buren","year":"2011","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1053\/j.ackd.2017.11.002_bib17","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib18","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1001\/archinte.1996.00440030080010","article-title":"Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study","volume":"156","author":"Ravid","year":"1996","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib19","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1046\/j.1523-1755.2002.00213.x","article-title":"Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes","volume":"61","author":"Schrier","year":"2002","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2017.11.002_bib20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1056\/NEJMoa013410","article-title":"Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes","volume":"347","author":"Lurbe","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/hr.2015.89","article-title":"Morning hypertension and night non-dipping in patients with diabetes and chronic kidney disease","volume":"38","author":"Oh","year":"2015","journal-title":"Hypertens Res"},{"key":"10.1053\/j.ackd.2017.11.002_bib22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.2040-1124.2011.00131.x","article-title":"Pathogenesis of diabetic nephropathy","volume":"2","author":"Cao","year":"2011","journal-title":"J Diabetes Investig"},{"key":"10.1053\/j.ackd.2017.11.002_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrneph.2011.51","article-title":"Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy","volume":"7","author":"Navarro-Gonzalez","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/ndt\/gfu411","article-title":"Diabetic nephropathy: landmark clinical trials and tribulations","volume":"31","author":"Chan","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2017.11.002_bib25","doi-asserted-by":"crossref","first-page":"697010","DOI":"10.1155\/2015\/697010","article-title":"Diabetic kidney disease pathophysiology and therapeutic targets","volume":"2015","author":"Toth-Manikowski","year":"2015","journal-title":"J Diabetes Res"},{"key":"10.1053\/j.ackd.2017.11.002_bib26","series-title":"Medical Clinics of North America. Diabetic Chronic Kidney Disease","first-page":"31","article-title":"The pathogenesis and management of hypertension in diabetic kidney disease","author":"Van Buren","year":"2013"},{"key":"10.1053\/j.ackd.2017.11.002_bib27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrneph.2014.74","article-title":"Therapeutic approaches to diabetic nephropathy- beyond the RAS","volume":"10","author":"Fernandez-Fernandez","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00109-012-0894-z","article-title":"Emergence and evolution of the renin-angiotensin-aldosterone system","volume":"90","author":"Fournier","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"10.1053\/j.ackd.2017.11.002_bib29","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1681\/ASN.2006040356","article-title":"Renin-angiotensin-aldosterone system and progression of renal disease","volume":"17","author":"Ruster","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib30","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1681\/ASN.V10112382","article-title":"The paradox of the low renin state in diabetic nephropathy","volume":"10","author":"Price","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib31","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1152\/physrev.00036.2005","article-title":"Physiology of local renin-angiotensin systems","volume":"86","author":"Paul","year":"2006","journal-title":"Physiol Rev"},{"key":"10.1053\/j.ackd.2017.11.002_bib32","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1254\/jphs.CPJ06008X","article-title":"Tissue angiotensin II generating system by angiotensin-converting-enzyme and chymase","volume":"100","author":"Miyazaki","year":"2006","journal-title":"J Pharmacol Sci"},{"key":"10.1053\/j.ackd.2017.11.002_bib33","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000313363","article-title":"Role of intrarenal renin-angiotensin-aldosterone system in chronic kidney disease","volume":"31","author":"Siragy","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib34","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1172\/JCI10963","article-title":"Ornithine decarboxylase, kidney size, and the tubular hypothesis of glomerular hyperfiltration in experimental diabetes","volume":"107","author":"Thomson","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1053\/j.ackd.2017.11.002_bib35","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1093\/ndt\/gfn377","article-title":"Activation of the renal renin-angiotensin system in diabetes\u2013new concepts","volume":"23","author":"Peti-Peterdi","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2017.11.002_bib36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2337\/dbi16-0056","article-title":"Back to the future: glomerular hyperfiltration and the diabetic kidney","volume":"66","author":"Tuttle","year":"2017","journal-title":"Diabetes"},{"key":"10.1053\/j.ackd.2017.11.002_bib37","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/HYPERTENSIONAHA.107.107268","article-title":"The collecting duct is the major source of Prorenin in diabetes","volume":"51","author":"Kang","year":"2008","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2017.11.002_bib38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1681\/ASN.2009030300","article-title":"The Biology of the (Pro)Renin receptor","volume":"21","author":"Nguyen","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib39","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/sj.ki.5000011","article-title":"Renin increases mesangial cell transforming growth factor-Beta 1 and matrix proteins hrough receptor-mediated, angiotensin II independent mechanisms","volume":"69","author":"Huang","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2017.11.002_bib40","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1681\/ASN.2006091062","article-title":"Slowly progressive, angiotensin II- independent glomerulosclerosis in human (Pro)Renin receptor- transgenic rats","volume":"18","author":"Kaneshiro","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib41","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1210\/en.2009-0442","article-title":"Glucose promotes the production of Interleukine-1\u03b2 and Cyclooxygenase-2 in mesangial cells via enhanced (Pro)Renin receptor expression","volume":"150","author":"Huang","year":"2009","journal-title":"Endocrinology"},{"key":"10.1053\/j.ackd.2017.11.002_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11906-010-0172-9","article-title":"Renin and prorenin receptor in hypertension: what's new?","volume":"13","author":"Nguyen","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"10.1053\/j.ackd.2017.11.002_bib43","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.amjhyper.2005.11.014","article-title":"Intratubular angiotensinogen in hypertension and kidney diseases","volume":"19","author":"Kobori","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ackd.2017.11.002_bib44","first-page":"29","article-title":"Inhibition of RAS in diabetic nephropathy","volume":"8","author":"Yacoub","year":"2015","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"10.1053\/j.ackd.2017.11.002_bib45","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1124\/pr.59.3.3","article-title":"The intrarenal renin-angiotensin system: from physiology to pathobiology of hypertension and kidney disease","volume":"59","author":"Kobori","year":"2007","journal-title":"Pharmacol Rev"},{"key":"10.1053\/j.ackd.2017.11.002_bib46","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1097\/01.ASN.0000071512.93927.4E","article-title":"Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II mediated renal and vascular disease","volume":"14","author":"Huang","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"8 Suppl B","key":"10.1053\/j.ackd.2017.11.002_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.18553\/jmcp.2007.13.s8-b.9","article-title":"The renin-angiotensin system: pathophysiological role and pharmacologic inhibition","volume":"13","author":"Atlas","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1053\/j.ackd.2017.11.002_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3317\/jraas.2006.003","article-title":"Role of angiotensin II in cardiovascular disease- therapeutic implications of more than a century of research","volume":"7","author":"Ferrario","year":"2006","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1053\/j.ackd.2017.11.002_bib49","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.amjmed.2003.09.034","article-title":"The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease","volume":"116","author":"Brewster","year":"2004","journal-title":"Am J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib50","doi-asserted-by":"crossref","first-page":"F632","DOI":"10.1152\/ajprenal.00462.2004","article-title":"AT1 receptor mediated enhancement of collecting duct renin in angiotensin II-dependent hypertensive rats","volume":"289","author":"Prieto-Carrasquero","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ackd.2017.11.002_bib51","first-page":"F366","article-title":"Control of glomerular filtration rate by renin-angiotensin system","volume":"233","author":"Hall","year":"1977","journal-title":"Am J Physiol"},{"key":"10.1053\/j.ackd.2017.11.002_bib52","first-page":"F459","article-title":"Glomerular hypertrophy accelerates hypertensive glomerular injury in rats","volume":"261","author":"Miller","year":"1991","journal-title":"Am J Physiol"},{"key":"10.1053\/j.ackd.2017.11.002_bib53","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1097\/01.ASN.0000127988.42710.A7","article-title":"Angiotensin II Type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats","volume":"15","author":"Hoffmann","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib54","first-page":"F1308","article-title":"Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat","volume":"291","author":"Whaley-Connell","year":"2006","journal-title":"Am J Physiol"},{"key":"10.1053\/j.ackd.2017.11.002_bib55","doi-asserted-by":"crossref","first-page":"F830","DOI":"10.1152\/ajprenal.00266.2007","article-title":"Activation of a local renin angiotensin system in podocytes by glucose","volume":"294","author":"Durvasula","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1053\/j.ackd.2017.11.002_bib56","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/ndt\/15.4.448","article-title":"Angiotensin II type 2 receptors in the kidney: evidence for endothelial-cell-mediated renal vasodilatation","volume":"15","author":"Arima","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2017.11.002_bib57","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1053\/j.ackd.2017.11.002_bib58","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1161\/01.HYP.0000196268.08909.fb","article-title":"Angiotensin converting enzyme 2 and angiotensin (1-7): an evolving story in cardiovascular regulations","volume":"47","author":"Ferrario","year":"2006","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2017.11.002_bib59","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1681\/ASN.2006050423","article-title":"Glomerular localization and expression of angiotensin converting enzyme-2 and angiotensin converting enzyme: implications for albuminuria in diabetes","volume":"17","author":"Ye","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib60","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2353\/ajpath.2007.060977","article-title":"Loss of angiotensin converting enzyme 2 (Ace2) accelerates diabetic kidney injury","volume":"171","author":"Wong","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1053\/j.ackd.2017.11.002_bib61","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1161\/HYPERTENSIONAHA.110.163519","article-title":"Intratubular renin-angiotensin System in hypertension","volume":"57","author":"Navar","year":"2011","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2017.11.002_bib62","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrneph.2012.249","article-title":"Key developments in renin\u2013angiotensin\u2013aldosterone system inhibition","volume":"9","author":"Sev\u00e1 Pess\u00f4a","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib63","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: the Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib64","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes: the Collaborative Study Group","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib65","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartain on renal and cardiovascular outcomes in type 2 diabetes and nephropathy: the RENAAL Study Investigators","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib66","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.2337\/diacare.25.11.1909","article-title":"Irbesartan reduces the albumin excretion rate in Microalbuminuric type 2 diabetic patients independently of hypertension","volume":"25","author":"Sasso","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2017.11.002_bib67","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1755-6686.2008.00032.x","article-title":"An evaluation of a self-management package for people with diabetes and risk of chronic kidney disease","volume":"34","author":"Thomas","year":"2008","journal-title":"J Renal Care"},{"key":"10.1053\/j.ackd.2017.11.002_bib68","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1681\/ASN.2013030285","article-title":"A randomized clinical trial of dietary sodium restriction in CKD","volume":"24","author":"McMahon","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib69","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE inhibition in non-diabetic nephropathies with non-nephrotic proteinuria","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2017.11.002_bib70","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1681\/ASN.2011040430","article-title":"Sodium intake, ACE inhibition, and progression to ESRD","volume":"23","author":"Vegter","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib71","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ki.2012.74","article-title":"Moderation of dietary sodium potentiates the renal and cardioprotective effects of angiotensin receptor blockers","volume":"82","author":"Lambers Heerspink","year":"2012","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2017.11.002_bib72","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/bmj.39147.604896.55","article-title":"Long term effects of dietary sodium reduction in cardiovascular disease outcomes: observational follow up of the trials of hypertension prevention (TOHP)","volume":"334","author":"Cook","year":"2007","journal-title":"Br Med J"},{"key":"10.1053\/j.ackd.2017.11.002_bib73","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/MNH.0000000000000073","article-title":"Dietary Sodium Restriction: a neglected therapeutic opportunity in chronic kidney disease","volume":"23","author":"Humalda","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/j.ackd.2017.11.002_bib74","series-title":"Sodium intake in populations: assessment of evidence","year":"2013"},{"key":"10.1053\/j.ackd.2017.11.002_bib75","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence based guideline for the management of high blood pressure in adults: report from panel members appointed to eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1053\/j.ackd.2017.11.002_bib76","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric effect of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib77","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ndt\/13.7.1682","article-title":"The blunting of the antiproteinuric effect of ACE inhibition by high Sodium intake can be restored by Hydrochlorothiazide","volume":"13","author":"Buter","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2017.11.002_bib78","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000358603","article-title":"Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study","volume":"39","author":"Agrawal","year":"2014","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib79","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1161\/CIRCOUTCOMES.111.962522","article-title":"Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT diabetes extension study","volume":"5","author":"Barzilay","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1053\/j.ackd.2017.11.002_bib80","first-page":"363","article-title":"KDIGO clinical practice guidelines for the management of blood pressure in chronic kidney disease","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ackd.2017.11.002_bib81","first-page":"S49","article-title":"Cardiovascular disease and risk management. Section 8 in standards of medical care in diabetes","year":"2015","journal-title":"Am Diabetes Care Suppl"},{"key":"10.1053\/j.ackd.2017.11.002_bib82","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition fro the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"issue":"9638","key":"10.1053\/j.ackd.2017.11.002_bib83","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET Study): a multicentre, randomised double-blind controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2017.11.002_bib84","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib85","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa042167","article-title":"Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: preventing microalbuminuria in type 2 diabetes","volume":"351","author":"Ruggenenti","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib86","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed dose of perindropril and indapamide on macrovascular and microvascular outcomes n patients with type 2 diabetes mellitus (The ADVANCE trial)","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2017.11.002_bib87","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1056\/NEJMoa1007994","article-title":"Prevention of albuminuria and cardiovascular morbidity with olmesartan: the ROADMAP trial","volume":"364","author":"Haller","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib88","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa0808400","article-title":"Renal and retinal effects of enalapril and losartan in type 1 diabetes","volume":"361","author":"Mauer","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib89","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(96)10244-0","article-title":"Randomized placebo controlled trial of lisinopril in normotensive patients with insulin dependent diabetes and normoalbuminuria or microalbuminuria","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2017.11.002_bib90","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and Micro-HOPE substudy","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2017.11.002_bib91","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/0003-4819-151-1-200907070-00120","article-title":"Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized controlled trials","volume":"151","author":"Bilous","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib92","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib93","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3410\/M2-18","article-title":"Renin angiotensin aldosterone (RAAS) inhibitors in the prevention of early renal disease in diabetes","volume":"2","author":"Gnudi","year":"2010","journal-title":"F1000 Med Rep"},{"key":"10.1053\/j.ackd.2017.11.002_bib94","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in Proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2017.11.002_bib95","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and occurrence of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib96","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1159\/000237742","article-title":"Predictors of hyperkalemia risk following hypertension control with aldosterone blockade","volume":"30","author":"Khosla","year":"2009","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib97","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1053\/j.ackd.2017.11.002_bib98","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib99","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1411487","article-title":"Sodium zirconium cyclosilicate in hyperkalemia","volume":"372","author":"Packham","year":"2015","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1053\/j.ackd.2017.11.002_bib100","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1524-6175.2004.4471.x","article-title":"Management of hypertensive chronic kidney disease: role of calcium channel blockers","volume":"7","author":"Toto","year":"2005","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1053\/j.ackd.2017.11.002_bib101","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/j.1523-1755.2004.00620.x","article-title":"Differential effects of calcium antagonist sub-classes on markers of nephropathy progression","volume":"65","author":"Bakris","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2017.11.002_bib102","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1001\/archinte.163.13.1555","article-title":"Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study","volume":"163","author":"Bakris","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib103","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0895-7061(01)02167-7","article-title":"Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists","volume":"14","author":"Weir","year":"2001","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ackd.2017.11.002_bib104","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"issue":"Suppl 1","key":"10.1053\/j.ackd.2017.11.002_bib105","first-page":"S28","article-title":"Implications of the United Kingdom prospective diabetes study","volume":"25","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2017.11.002_bib106","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2337\/dc11-1827","article-title":"The action to control cardiovascular risk in diabetes (ACCORD) blood pressure trial","volume":"35","author":"Barzilay","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1053\/j.ackd.2017.11.002_bib107","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/j.ackd.2017.11.002_bib108","doi-asserted-by":"crossref","first-page":"884","DOI":"10.7326\/0003-4819-144-12-200606200-00005","article-title":"Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?","volume":"144","author":"Messerli","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archinternmed.2011.619","article-title":"Blood pressure components and end-stage renal disease in person with chronic kidney disease: the Kidney Early Evaluation Program (KEEP)","volume":"172","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1053\/j.ackd.2017.11.002_bib110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1161\/HYPERTENSIONAHA.108.115154","article-title":"Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease","volume":"53","author":"Pogue","year":"2009","journal-title":"Hypertension"},{"key":"10.1053\/j.ackd.2017.11.002_bib111","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2017.11.002_bib112","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","year":"2010","journal-title":"J Am Soc Nephrol"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559517302033?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559517302033?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T21:16:35Z","timestamp":1660684595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559517302033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":112,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1548559517302033"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2017.11.002","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2017.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}